Table 6.

Adverse events occurring in more than 2% of patients in either treatment group.

Preferred term	ISC 17536, n = 72, n (%)	Placebo, n = 66, n (%)	Overall, N = 138, n (%)
Abdominal distension	1 (1.4)	2 (3.0)	3 (2.2)
Diarrhea	2 (2.8)	0	2 (1.4)
Dyspepsia	2 (2.8)	3 (4.5)	5 (3.6)
Throat irritation	1 (1.4)	3 (4.5)	4 (2.9)
Dysgeusia	2 (2.8)	1 (1.5)	3 (2.2)
Pain	2 (2.8)	0	2 (1.4)
Pyrexia	1 (1.4)	2 (3.0)	3 (2.2)
Blood creatine phosphokinase (CPK) increased	1 (1.4)	3 (4.5)	4 (2.9)
Blood potassium increased	2 (2.8)	2 (3.0)	4 (2.9)
Hyperglycemia	2 (2.8)	2 (3.0)	4 (2.9)
Hypoglycemia	0	3 (4.5)	3 (2.2)
Proteinuria	0	2 (3.0)	2 (1.4)